TUESDAY, JUNE 19, 2018

HPV cancer vaccine finishes successful trial

ORYX trial successful for HPV-associated cancer vaccine.
ORYX trial successful for HPV-associated cancer vaccine. | Courtesy of southerncytologysociety.com
ORYX, a company that produces translational medicines -- including cancer vaccines and oncolytic virotherapy --  said on Monday that its researchers successfully have completed their Phase I/IIa trial to test a vaccine for cancers associated with the Human Papilloma Virus (HPV).

The trial was conducted in an open lab and involved 26 patients who were required to have HPV-positive vulvar, cervical, vaginal, head, neck, penile or anal cancers at an advanced stage.

The vaccine, VicOryx, treats p16INK4a-overexpressing HPV-positive cancer patients. Before or after their standard therapies, the subjects received a diffuse expression of p16INK4a inside the tumor. The results showed that the vaccine is safe and provoked the body’s immune system into a response against the illness.

There are currently two prophylactic vaccines that stimulate HPV-type immunity, but these vaccines do not have the same therapeutic outcomes for HPV infections.

"We are pleased to announce another successful completion of another clinical trial,” Dr. Bernard Huber, CEO and Founder of ORYX, said. “The VicOryx trial has shown the important potential of our therapeutic p16 vaccine. Inspired by the ground-breaking HPV research of Nobel Laureate Professor (Harald) zur Hausen, member of the ORYX Scientific Advisory Board, and based on the VicOryx data, we are convinced that this vaccination approach can be an effective therapeutic strategy for patients with HPV-associated cancers."

The company will present its results at the BIO-European Conference in Paris this month.

Organizations in this Story

ORYX GmbH & Co. KG

Want to get notified whenever we write about ORYX GmbH & Co. KG ?
Next time we write about ORYX GmbH & Co. KG, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.